Following the program “Britain’s Tourette’s Mystery” that was aired on C4 last week which contained many inaccurate and misleading facts, Tourette’s Action UK has issues the following press release
Response by Tourette's Action to the Channel 4 documentary 'Britain's Tourettes Mystery'
Related Posts
Introducing Our Wellness Release
We want to share an important update on the Neupulse device and how we’re moving forward.As many of you know, we’ve been progressing through our planned medical device regulatory pathway. The aim was to complete this before launch, but we’ve hit a bottleneck in the process that has impacted our original timeline. Our goal has always been to get the Neupulse device into people’s hands as quickly as possible and we’re still committed to achieving that target. Our new approach for the release of our device To keep moving forward, we’ve made the decision to release a device focused on wellness use first, while continuing the medical device regulatory approval process in parallel. This approach allows us to begin delivering the benefits of the technology sooner, rather than delaying access while regulatory work continues. It’s important to be clear about what this means:The same core technology - The wellness device is built on the same underlying technology as the device progressing through medical device regulatory approval. No compromise on safety or quality - The device meets the same appropriate standards and quality requirements. We’re committed to delivering a safe and high-quality device. A different starting point - What’s changing is how the device is introduced at this stage. We still plan to start our phased UK launch in June 2026 and our long-term goals remain the same. Our long-term direction Our plans to release a medical device remain unchanged. We are continuing to pursue medical regulatory approval, and this remains a core part of our future. Launching a wellness product allows us to take a meaningful step forward now, while continuing that work in parallel. Why we’re taking this approach Regulatory timelines for medical devices can be unpredictable. Rather than waiting, we’ve chosen a path that allows us to: Put the device into people's hands sooner Enable people to benefit from our technology earlier Continue progressing responsibly towards regulatory approval Join the conversation We know this update may raise questions, and we want to make sure our community feels informed and involved. You can find some FAQs on our help page that hopefully address some of your initial questions. We will be hosting live online sessions in the coming weeks where you can hear from us directly on our move to wellness and our upcoming device launch. Our customer experience team is ready to answer your questions. Simply email enquiries@neupulse.co.uk.Moving forward We’re incredibly grateful for the support and belief that has brought us to this point. We will continue to keep you updated while pushing ahead with our phased UK launch in June 2026 as planned. The Neupulse Team
Learn more
Neupulse raises £3 million to accelerate delivery of its neurotherapeutic technology
Neupulse Press Release, Nottingham, UK - Neupulse, a neurotherapeutics company focused on delivering innovative solutions to people with brain health conditions, like Tourette Syndrome, has announced it has successfully raised £3 million in new funding. The round was led by Eos Advisory and the Midlands Engine Investment Fund II, through appointed fund manager Mercia Ventures, with participation from existing and new investors. The funding will be used to scale sales and accelerate Neupulse’s path to market, supporting product development, regulatory progress and early commercialisation, to ensure the company’s technology reaches individuals who need it most. The funding comes at a time when venture and growth funding remains highly constrained, underscoring the strength of Neupulse’s proposition and the confidence investors have in both the company’s mission and execution. Neupulse’s continued momentum highlights growing demand for effective, clinically grounded neurotherapeutic solutions and positions Neupulse strongly for its next phase of growth. Neupulse’s product is designed to address critical gaps in current treatment options, combining scientific rigour with a clear focus on real-world impact. This funding round enables the company to move decisively from development towards commercial launch in mid-2026, while continuing to build the evidence base required by clinicians, regulators, and healthcare systems. The company first secured funding from the Midlands Engine Investment Fund II in 2024 to finalise development of a non-drug treatment to help manage the symptoms of Tourette’s Syndrome. The £500,000 investment helped Neupulse’s continued research into the TS therapy wristband device and clinical trials. Eos and Mercia Ventures are both experienced backers of high-growth healthcare and deep-tech businesses, bringing not only capital but strategic expertise to support Neupulse. Their continued leadership reflects a shared belief in the company’s long-term potential and its ability to generate both commercial and clinical value. Paul Cable, CEO, Neupulse said: “This investment underlines the unmet need in providing people with conditions like Tourette Syndrome a solution to manage their condition, and as a company, we are driven to improve the lives of individuals with these conditions.” Ian Rhodes, Chair of the board at Neupulse, added: “This is a great example of advanced biomedical research from a leading UK university creating an initial UK market launch during 2026. This will increasingly benefit the UK economy as the technology scales out globally.” David Tindall, Senior Investment Manager at the British Business Bank, said: “Neupulse’s growth over the past year, following investment from the Midlands Engine Investment Fund II, has been impressive. By addressing a clear gap in the market and delivering a much-needed solution for those affected, the business exemplifies the Fund’s commitment to backing ambitious, high-growth companies. This latest round of funding will further support Neupulse in developing and launching new treatment options.” Andrew McNeill, Investor Director at Eos, said: "We are delighted to support the next chapter of Neupulse as they move towards commercialisation. This is exactly the kind of company and science we like to back. Passionate founders and technology with the potential to positively impact the lives of people across the globe.” Sandy Reid, Fund Principal, Mercia Ventures added: “Tourette Syndrome is believed to affect up to two per cent of all children worldwide but currently the only treatments are medication and behavioural therapy, neither of which are ideal solutions. Neupulse’s device offers a genuine alternative that could transform lives.” The £400m Midlands Engine Investment Fund II covers the entire Midlands region and provides debt finance from £25k to £2m and equity investment up to £5m to help a range of small and medium sized businesses to start up, scale up or stay ahead. The purpose of the Midlands Engine Investment Fund II is to drive sustainable economic growth by supporting innovation and creating local opportunity for new and growing businesses across the Midlands. The Midlands Engine Investment Fund II will increase the supply and diversity of early-stage finance for smaller businesses in the Midlands, providing funds to firms that might otherwise not receive investment and help to break down barriers in access to finance. About Neupulse Neurotherapeutics Ltd was founded in 2021 as a spin-out from the University of Nottingham, commercialising the research of Professor Stephen Jackson, Professor Georgina Jackson and Dr Barbara Morera. We are a neurotechnology company pioneering non-invasive neuromodulation solutions to improve quality of life for people living with neurological and mental health conditions. Combining neuroscience and user-centric design, Neupulse develops wearable technologies that deliver effective and drug free solutions. Our mission is to make our neuromodulation therapies available to everyone, empowering individuals to take control of their neurological health. About Mercia Ventures Mercia Ventures is a proactive venture capital investor focused on being the first-choice partner for growth. Mercia Ventures makes equity investments of up to £10million across all sectors, with specialisms in Software, Consumer, Healthcare and Deep Tech. Mercia Ventures is a trading name of investment funds managed by Mercia Fund Management Limited and Mercia Regional Ventures Limited, part of the Mercia Asset Management PLC Group, and sits alongside the Group’s wider private equity, debt and proprietary balance sheet operations. The Group has 11 offices in the UK, and Mercia Ventures’ national footprint and 48 strong investment team draws on their experiences as founders, PhD scientists, software engineers, corporate financiers and management consultants to help our partner companies successfully achieve their ambitions. Mercia Asset Management PLC has c.£2 billion of assets under management. Mercia Asset Management PLC is quoted on AIM with the epic "MERC". The Group raises its own Venture Capital Trusts (VCTs) and Enterprise Investment Scheme (EIS) Funds, and details about open offers can be found through Mercia’s website. Mercia Asset Management PLC is quoted on AIM with the epic "MERC" and includes the following wholly owned subsidiaries: Mercia Fund Management Limited is authorised and regulated by the FCA under firm reference number 524856 Mercia Regional Ventures Limited is authorised and regulated by the FCA under firm reference number 183363 Mercia Business Loans Limited is authorised and regulated by the FCA under firm reference number 443560 Frontier Development Capital Limited is authorised and regulated by the FCA under firm reference number 829697 www.mercia.co.uk About the Midlands Engine Investment Fund II Operated by the British Business Bank, the Midlands Engine Investment Fund II (MEIF II) provides a mix of debt and equity funding. MEIF II offers a range of commercial finance options with small loans from £25k to £100k, debt finance from £100k to £2m and equity investment up to £5 million. It works alongside the Combined Authorities, Local Enterprise Partnerships (LEPs), and Growth Hubs, as well as local intermediaries such as accountants, fund managers and banks, to support smaller businesses in the Midlands at all stages of their development. The funds in which the MEIF II invests are open to businesses with material operations, or planning to open material operations, in the West and East and South East Midlands. Supported by Nations and Regions Investments Limited, a subsidiary of British Business Bank plc, the Bank is a development bank wholly owned by HM Government. Neither Nations and Regions Investments Limited nor British Business Bank plc are authorised or regulated by the Prudential Regulation Authority (PRA) or the Financial Conduct Authority (FCA). For investment by MEIF II sub-fund at the investee company level. The investment from the Midlands Engine Investment Fund II into Neupulse does not amount to any endorsement or warranty from Nations and Regions Investments Limited, the British Business Bank plc or the government of the United Kingdom. About Eos Advisory Eos Advisory invests in and commercialises science and technology at local seed-stage, with the potential to scale globally, and with a focus on improving the health of people and the planet. Founded in St. Andrews in 2014, Eos is the trusted link between non-specialist Investors and highly specialist, knowledge intensive technology companies, building a portfolio of companies developing innovations to improve disease diagnostics, prevention, and treatment, environmental sustainability, and food and water security. Eos works in partnership with family offices, individuals, companies, and institutional investors who invest through an annual, EIS qualifying Innovation Fund, and an Investment Syndicate: https://eos-advisory.com
Learn more
I Swear Trailer Released: A True Tourette Syndrome Story Featuring Neupulse
The official trailer for I Swear, directed by BAFTA-nominated filmmaker Kirk Jones, has just been released and it’s nothing short of powerful. Set for release in UK cinemas on 10 October 2025, I Swear tells the extraordinary true story of John Davidson, a campaigner, speaker, and inspiration for the Tourette Syndrome community. For Neupulse, this movie is deeply personal on a few levels. Not only is John’s story close to our mission, but excitingly our technology also features in the film. A Story That Needed to Be Told The film charts John Davidson’s journey from a misunderstood teenager in a small Scottish town to an outspoken advocate for people living with Tourette Syndrome. Diagnosed at age 15, John faced isolation, ridicule, and even the threat of institutionalisation, at a time when very few understood what Tourette Syndrome actually was. His vocal and motor tics started to have a huge impact on his daily life, often misunderstood by peers, teachers, and even healthcare professionals. But I Swear isn’t just about struggle, it’s about resilience. It’s about the humour, heart, and community that helped John thrive despite the odds. It’s about finding the strength to live loudly and authentically. A Glimpse Into John’s World The official trailer, distributed by the film company StudioCanal, introduces us to John (played by Robert Aramayo) as a teenager trying to make sense of his rapidly changing body and mind. Highlighted in the trailer are situations John finds himself in time and time again. His tics affecting his home life, school, work and his place in the wider world. Amongst all these snapshots we see the full range of emotions that can come with tics. Anger, pain, rejection, humour, and so much more. As a viewer it's a rollercoaster too, being pulled between laughter (“Spunk for milk!”) and tears, the trailer perfectly setting the tone of a film that attempts to walk some fine lines. The film doesn’t shy away from John’s emotional struggles, but nor does it reduce him to them. This is a full, nuanced portrayal of a young man navigating misunderstanding and self-discovery. His story becomes not only one of survival but of transformation. A Stellar Line-up of British Talent Taking on the lead role is Robert Aramayo, best known for his performances in The Rings of Power and The King’s Man. Aramayo reportedly spent time with John Davidson and his family in Galashiels to understand his personality and mannerisms. His portrayal is already earning praise for its depth and sensitivity. Joining Aramayo are screen icons Maxine Peake as Dottie Achenbach, one of John’s key supporters. Shirley Henderson plays his mother Heather Davidson. The cast is rounded out by Peter Mullan, playing Tommy Trotter, a compassionate teacher who becomes instrumental in John’s life. This combination of talent, lived experience, and genuine heart gives I Swear the authenticity and emotional punch it needs. The Vision of Kirk Jones Director and writer Kirk Jones is no stranger to stories with heart. Known for hits like Waking Ned, Nanny McPhee, and My Big Fat Greek Wedding 2, Jones brings his signature warmth and understated humour to this emotionally charged script. Jones was reportedly moved by John Davidson’s story after watching a BBC documentary about him years ago. From there, he worked closely with John and his family to develop a screenplay that honoured their journey while making the story accessible to a wider audience. TS in the Spotlight One of the film’s most important achievements is its accurate, layered portrayal of Tourette Syndrome, a condition so often reduced to a punchline in popular culture. Instead of focusing only on coprolalia (the involuntary swearing many people wrongly assume defines the condition), I Swear digs into the daily experience of living with a neurological disorder that affects speech, movement, and self-image. It explores the impact not just on John, but on the people around him. For viewers unfamiliar with Tourette Syndrome, the film is an education. For those living with TS, it’s a representation of some of the challenges faced. And for everyone watching, it’s a call to empathy. Neupulse Part Of The Story We’re so proud to share that Neupulse plays a role in I Swear. Without revealing too much, we can confirm that our wearable neurotechnology - designed to help manage tics in people with Tourette Syndrome - is featured in the film. John has been a vital part of our journey at Neupulse. His insight, experience, and unfiltered honesty, along with other members of the TS community, has shaped the way we think about support, accessibility, and the lived experience of those with Tourette Syndrome. Why This Film Matters Representation in media matters. When real, honest stories are told, with empathy, humour, and respect, they have the power to shift public perception and inspire real change. I Swear is more than a film. It’s a testament to what happens when someone refuses to be silenced. It’s a reminder that behind every medical condition is a human being with dreams, fears, jokes, and stories to tell. And it’s a celebration of the progress being made, from outdated treatments and harmful stigma to innovation, visibility and hope. At Neupulse, we believe in empowering people with Tourette Syndrome, not just with devices, but with dignity. That’s why this film feels so important to us. Popcorn At The Ready We can't wait to watch the movie! The trailer for I Swear sets the stage for what promises to be one of the most moving and necessary British films of the year. With a talented cast, an acclaimed director, and a story grounded in truth, it’s a must-see for anyone who believes in the power of storytelling to drive change. We’re incredibly proud that Neupulse is part of this cinematic journey. We’ll be sharing more about how we feature in the film, and what it means for the community, in the coming months. Let us know what you think of the trailer and what moments stood out most. We’d love to hear from you. #ISwearFilm #Neupulse #TourettesAwareness #Neurodiversity #JohnDavidson #NeupulseInFilm
Learn more